Digest Network Come funziona
Network
/
Società
Io
Non verificato

Ionis Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

84 comunicati stampa

Guarda tutti i comunicati
23/10/2026
Farmaceutica
Salute
Medicina - Varie
Eventi
Industria
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
22/10/2026
Associazioni/Professionisti
Salute
Risorse Umane
Farmaceutica
Biotecnologia
Analisi di mercato
Eventi
Ionis ranked #1 on Science’s Top Employers list 
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
16/10/2026
Cardiologia
Farmaceutica
Comunicazione
Sanità
Salute
Biotecnologia
Medicina - Varie
Industria
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
23/09/2026
Industria
Salute
Scienza
Farmaceutica
Medicina - Varie
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
22/09/2026
Industria
Farmaceutica
Sanità
Salute
Igiene alimentare
Comunicazione
Biotecnologia
Medicina - Varie
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/09/2026
Industria
Farmaceutica
Salute
Medicina - Varie
Cardiologia
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/09/2026
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/09/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Ionis to present at upcoming investor conferences
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
20/08/2026
Web e Social Network
Fiere
Eventi
Salute
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Biotecnologia
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/07/2026
Mercato del lavoro
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0